| INTRODUCTION
Hyperthyroidism in cats is a debilitating and potentially lifethreatening endocrine disorder that affects up to 10% of geriatric cats. 1 The hypermetabolic effects of untreated hyperthyroidism can
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result in numerous adverse sequelae such as weight loss, behavioral changes, muscle wasting, malnutrition, heart disease, and hypertension, among others. 2 Although several treatment options exist, radioactive iodine therapy with 131 I is widely considered to be the treatment of choice. A single treatment is curative in approximately 95% of cases, and complications are uncommon, occurring in less than 5% of cases. [2] [3] [4] Despite these positive aspects, radioactive iodine therapy is not without limitations. Most treatment protocols require in-hospital isolation times of 3-9 days. 4, 5 Consequently, cats that are intolerable of prolonged isolation because of demeanor or concurrent medical conditions are poor candidates for 131 I therapy. Treatment costs, which are currently $1200-$1900 at our institutions, also are prohibitive for many owners. Beyond these limitations, cat excreta remains radioactive for weeks and could be a source for human radiation exposure. 5, 6 Ideal dosing regimens for 131 I have not been established, and protocols vary among institutions. 3, 4 Regardless, mechanisms to increase thyroidal radioactive iodine uptake (RAIU) would allow utilization of lower treatment doses, thereby addressing many current limitations.
Recombinant human thyroid stimulating hormone (rh-TSH) administration has been shown to result in dose-dependent increases in thyroidal RAIU in humans. 7, 8 This strategy has been used in humans to reduce radioactive iodine doses for treatment of thyroid neoplasia and nodular goiter.
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The effects of TSH administration on RAIU are not well described in companion animals, and discordant results have been reported.
Bovine TSH administration increases RAIU in healthy dogs. 11 However, these results were contradicted in another study in which rh-TSH administration had no effect on RAIU in dogs. 12 In a small pilot study of hyperthyroid cats, RAIU was increased by administration of 25 μg rh-TSH, but changes were heterogeneous and of questionable clinical utility. 13 The authors speculated that increased rh-TSH doses could have resulted in greater and more consistent increases in RAIU. 13 Indeed, an in vitro study has shown that responsiveness of feline thyroid cells to TSH is dose dependent, and hyperthyroid cells require higher TSH concentrations than do normal cells to stimulate cellular activity and thyroglobulin expression. 14 Given current knowledge gaps, it is apparent that more detailed investigations of rh-TSH in hyperthyroid cats are warranted. The objective of this study was to investigate the effects of higher doses of rh-TSH on RAIU in cats with hyperthyroidism. In addition, potential associations of serum thyroid hormone concentrations with RAIU were investigated. We hypothesized that rh-TSH administration would result in dose-dependent increases in RAIU.
| MATERIAL AND METHODS

| Study design
A randomized, placebo-controlled, crossover study was conducted to investigate the effects of two doses of rh-TSH on RAIU in cats with hyperthyroidism. A sample size calculation was performed using data from previous studies. 12, 13, 15 The analysis suggested 9 cats would be needed to detect an approximate 15% difference in RAIU between rh-TSH doses with power of 0. Cats were treated with IV administration of 2 mL 0.9% saline (placebo), 50 μg rh-TSH (low-dose), and 100 μg rh-TSH (high-dose) in randomized crossover design. Pharmaceutical grade rh-TSH (Thyrogen; Sanofi Genzyme, Cambridge, Massachusetts) was reconstituted with sterile saline, stored in aliquots of 50 or 100 μg at −20 C, and used within 14 weeks. Aliquots were allowed to thaw at room temperature immediately before use. Randomization order was determined using a random number generator (Microsoft Excel), and each treatment was separated by 7-10 days to allow sufficient washout for possible TSH effects. 16, 17 Thyroid scintigraphy examinations were performed after each treatment to assess RAIU.
| Thyroid scintigraphy
Thyroid scintigraphy examinations were performed using 123 I as described previously. 13, 18 One hour after rh-TSH/placebo administration, a 300 μCi dose of 123 I was administered PO followed by 3-4 mL of water to ensure passage of capsules into the stomach. Thyroidal RAIU was assessed using a planar gamma camera using a low energy, radioimmunoassay (Free T 4 -by Equilibrium Dialysis, Antech Diagnostics, Irvine, California) that previously has been described by the laboratory. 19 Serum concentrations of total T 3 were measured with an inhouse charcoal-separation radioimmunoassay where the procedures 20 and use in feline serum 21 
| Confirmation of rh-TSH bioactivity
Aliquots of rh-TSH were stored until after study completion to ensure that rh-TSH storage did not affect bioactivity. After completion of the study, rh-TSH stimulation testing was performed in 4 healthy cats using banked aliquots of rh-TSH. The aliquots, which had been stored at −20 C for 20 weeks, contained 50 μg rh-TSH. The cats were members of a breeding colony and were deemed healthy on the basis of normal physical and laboratory examinations. The age and weight ranges of the cats were 2.5-7 years and 2.8-5.5 kg, respectively.
Serum total T 4 concentrations were measured immediately before and 6 hours after IV administration of 50 μg rh-TSH. The mean AE standard deviation (SD) total T 4 concentrations increased from a baseline of 24.3 AE 4.6 to 79.5 AE 9.2 nmol/L at 6 hours (P < .001). This 3-fold increase in total T 4 concentrations was within the expected range of responses for healthy cats, 17 thus confirming the bioactivity of the rh-TSH used herein.
| Statistical analysis
Thyroidal iodine uptake data followed a normal distribution as assessed , were performed to further investigate relationships between thyroidal iodine uptake and serum thyroid hormone concentrations. Statistical analyses were performed using commercially available software (SAS, version 9.3; SAS Institute Inc, Cary, North Carolina), and for all analyses, P ≤ .05 was considered significant.
| RESULTS
Ten cats, 5 spayed females, and 5 neutered males met inclusion criteria and participated in the study. The median age of the cats was 
| DISCUSSION
In this study of 10 cats with naturally occurring hyperthyroidism, 50 and 100 μg doses of rh-TSH failed to consistently increase thyroidal RAIU. In humans with nodular goiter, single dose administration of 10 or 30 μg rh-TSH doubles 24 hour RAIU. 23 Therefore, rh-TSH administration can be used to achieve 50%-60% reductions in radioiodine doses in humans with nodular goiters. 8 Recombinant human TSH administration also can be used in a similar manner in humans to facilitate thyroidal remnant ablation for incompletely excised or metastatic thyroid cancer after thyroidectomy. 24 This strategy also obviates the need for cessation of thyroid supplementation before radioiodine therapy. 10 The results of our study suggest that rh-TSH administration is unlikely to have any benefit for the treatment of hyperthyroidism in cats. The reasons for this lack of effect in cats FIGURE 1 Scatterplot depicting radioactive iodine uptake (RAIU) in hyperthyroid cats after treatment with saline (placebo, n = 10), 50 μg recombinant human thyroid stimulating hormone (rh-TSH) (low-dose, n = 8), and 100 μg rh-TSH (high-dose, n = 10). The center and outer horizontal lines represent mean and stadard deviation (SD), respectively. The RAIUs were calculated at 8-and 24-hour time points after 300 μCi 123 I administration. does not respond to TSH. This would be consistent with previous reports in which TSH stimulation testing failed to consistently increase serum thyroid hormone concentrations in hyperthyroid cats. 13, 25, 26 It is noteworthy that our findings contradict the results of a previous study of 5 hyperthyroid cats in which increases in RAIU were reported in response to 25 μg rh-TSH administration. 13 There were several methodologic differences between studies that might account for the different results. In this study, we randomized treatment order, used higher rh-TSH doses, and blinded our radiologist to treatment group. The times of scanning in relation to rh-TSH and 123 I administration also were slightly different. It is unknown if these or other factors are responsible for the discrepancies. In the previous report, RAIU increased by 20% in one cat in response to rh-TSH. In our study, only 1 of 10 cats experienced a change of similar magnitude which occurred at the 8-hour time point (19.2%-37.5% RAIU) after 100 μg rh-TSH administration. Interestingly, most cats in our report actually experienced decreases in RAIU after both 50 and 100 μg rh-TSH administration. Differences in RAIU among treatment groups were trivial in the majority of cats. As such, the authors believe that differences in RAIU in individual cats are likely a result of intrasubject variation that is independent of any true rh-TSH effect. Regardless, even if the rh-TSH administration did increase the RAIU percent by a value between 0% (reported herein) and 7% (reported previously), the effect would not be of clinical relevance.
The possibility of alternate rh-TSH administration protocols resulting in increased RAIU cannot be excluded. For instance, the typical rh-TSH dosing protocol used for thyroid remnant ablation in humans is 2 doses of 900 μg, given 24 hours apart, followed by 131 I administration 24 hours later. 24 A similar protocol in veterinary medicine would offset the potential cost-saving benefits and reduction in hospitalization times that could be achieved with a one-time rh-TSH administration protocol. Furthermore, it is unknown if repeated rh-TSH administration could recruit previously atrophied nondiseased thyroid tissue and increase the risk of treatment-induced hypothyroidism. One study of humans with nontoxic nodular goiter suggested maximum increases in RAIU in response to rh-TSH actually occurred the day after rh-TSH administration. 23 It is possible that a delayed effect also could occur in hyperthyroid cats. However, significant increases in RAIU are still observed on the day of rh-TSH administration in humans with nontoxic nodular goiter, 23 One alternative strategy to achieve this aim would be dietary iodine restriction before 131 I therapy to reduce available iodine and create an environment for optimal radioiodine uptake. 18, 28 Dietary iodine restriction has been recommended for 5 days to 4 weeks preceding 131 I administration in humans with thyroid carcinoma. 28 There is evidence that dietary iodine restriction can alter RAIU in hyperthyroid cats, but this intriguing premise requires further investigation. 18 Although not a primary study aim, we did observe positive correlations between serum thyroid hormones and RAIU. Serum total T 4 , free T 4 , and total T 3 were positively correlated with RAIU at 8 hours, but only free T 4 concentrations remained significantly correlated at 24 hours. Similar relationships have been reported previously in hyperthyroid cats, and thyroid hormone concentrations also have been shown to positively correlate with estimated thyroid volume. 
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